clinmedКлиническая медицинаClinical Medicine (Russian Journal)0023-21492412-1339ООО «Медицинское информационное агентство»10.30629/0023-2149-2026-104-6-417-423clinmed-1490Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESНовый взгляд на антикоагулянтную терапию: абелацимаб и ультразвуковая эндоваскулярная тромбэктомическая система EKOSA new approach to anticoagulant therapy: abelacimab and the EKOS ultrasonic endovascular thrombectomy systemhttps://orcid.org/0000-0002-1183-3441АрдашевВ. Н.ArdashevV. N.

Ардашев Вячеслав Николаевич — д-р мед. наук, профессор, научный руководитель по терапии

Москва

Vyacheslav N. Ardashev — Doctor of Medical Sciences, Professor, Scientifi c Director of Therapy

Moscow

ФроловВ. М.FrolovV. M.

Фролов Виктор Михайлович — канд. мед. наук, доцент, врач функциональной диагностики

Москва

Victor M. Frolov — Candidate of Medical Sciences, Associate Professor, Functional Diagnostics Physician

Moscow

https://orcid.org/0000-0002-6851-5786НовиковЕ. М.NovikovE. M.

Новиков Егор Михайлович — канд. мед. наук, заведующий кардиологическим отделением КДЦ; врач-кардиолог  

Москва

Egor M. Novikov — Candidate of Medical Sciences, Head of the Cardiology Department; cardiologist

Moscow

dr.enovikov@gmail.comСтепановМ. М.StepanovM. M.

Степанов Максим Маркович — канд. мед. наук, заведующий кардиологическим отделением №2

Москва

Maxim M. Stepanov — Candidate of Medical Sciences, Head of the Cardiology Department No. 2

Moscow

МясоедоваЕ. И.MyasoedovaE. I.

Мясоедова Екатерина Игоревна — д-р мед. наук, заместитель главного врача по клинико-экспертной работе, врач ультразвуковой диагностики

Москва

Ekaterina I. Myasoedova — Doctor of Medical Sciences, Deputy Chief Physician for Clinical and Expert Work, Ultrasound Diagnostics Doctor

Moscow

https://orcid.org/0009-0003-4844-4401ДорджиеваВ. В.DordjievaV. V.

Дорджиева Виктория Владимировна — студентка 5-го курса; медицинская сестра

Москва

Victoria V. Dordjieva — 5th-year student; a nurse 

Moscow

https://orcid.org/0009-0007-1342-4100ГерасименкоЕ. А.GerasimenkoE. A.

Герасименко Екатерина Алексеевна — студентка 5-го курса; медицинская сестра

Москва

Ekaterina A. Gerasimenko — 5th-year student; nurse

Moscow

https://orcid.org/0000-0002-7185-4324ГлобаИ. В.GlobaI. V.

Глоба Ирина Владимировна — канд. мед. наук, ассистент кафедры судебной медицины

Москва

Irina V. Globa — Candidate of Medical Sciences, Assistant Professor at the Department of Forensic Medicine 

Moscow

ФГБУ «Клиническая больница № 1» Управления делами Президента Российской ФедерацииРоссияClinical Hospital No. 1 of the Administrative Directorate of the President of the Russian FederationRussian FederationФГУП «Главное производственно-коммерческое управление по обслуживанию дипломатического корпуса при МИД РФ», филиал «МединЦентр»РоссияMain Production and Commercial Directorate for Servicing the Diplomatic Corps of the Ministry of Foreign Aff airs of the Russian Federation, MedinCenter BranchRussian FederationФГБУ «Клиническая больница № 1» Управления делами Президента Российской Федерации; ФГУП «Главное производственно-коммерческое управление по обслуживанию дипломатического корпуса при МИД РФ», филиал «МединЦентр»РоссияClinical Hospital No. 1 of the Administrative Directorate of the President of the Russian Federation; Main Production and Commercial Directorate for Servicing the Diplomatic Corps of the Ministry of Foreign Aff airs of the Russian Federation, MedinCenter BranchRussian FederationФГУП «Главное производственно-коммерческое управление по обслуживанию дипломатического корпуса при МИД РФ», филиал «МединЦентр»; ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский университет)РоссияMain Production and Commercial Directorate for Servicing the Diplomatic Corps of the Ministry of Foreign Aff airs of the Russian Federation, MedinCenter Branch; I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russia (Sechenov University)Russian FederationФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский университет)РоссияI.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russia (Sechenov University)Russian Federation2026280820261046417–423Copyright © Ардашев В.Н., Фролов В.М., Новиков Е.М., Степанов М.М., Мясоедова Е.И., Дорджиева В.В., Герасименко Е.А., Глоба И.В., 20262026Ардашев В.Н., Фролов В.М., Новиков Е.М., Степанов М.М., Мясоедова Е.И., Дорджиева В.В., Герасименко Е.А., Глоба И.В.Ardashev V.N., Frolov V.M., Novikov E.M., Stepanov M.M., Myasoedova E.I., Dordjieva V.V., Gerasimenko E.A., Globa I.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinmedjournal.com/jour/article/view/1490

Статья посвящена новым подходам в антитромботической и антикоагулянтной терапии: абелацимабу — современному высокоселективному ингибитору фактора XI и минимально инвазивной системе для растворения тромба EKOS Boston Scientific. В работе анализируются уникальные механизмы действия абелацимаба, раскрывающие терапевтический потенциал по сравнению с традиционными антикоагулянтами и возможные области его применения в клинической практике. Подробно рассматриваются фармакокинетические особенности препарата, в частности быстрое начало эффекта (в течение 30 мин ) и исключительная продолжительность действия (свыше 30 дней). Особое внимание уделено клиническим показаниям к использованию абелацимаба и способам введения, что является важным аспектом для практического применения препарата. Во второй части статьи рассказывается о возможности использования ультразвуковой эндоваскулярной тромбэктомической системы EKOS Boston Scientifi c для минимально инвазивного растворения тромбов, что может сочетаться с эффектом абелацимаба. Приводится клинический пример успешного применения системы EKOS у пациента с окклюзирующим тромбозом глубоких вен нижней конечности.

The article focuses on new approaches to anticoagulation: abelacimab, a modern, highly selective factor XI inhibitor, and the Boston Scientifi c EKOS minimally invasive clot dissolution system. This paper analyzes the unique mechanisms of action of abelacimab, revealing its therapeutic potential compared to traditional anticoagulants, and its potential applications in clinical practice. The drug's pharmacokinetic properties are discussed in detail, particularly its rapid onset of action (within 30 minutes) and exceptional duration of action (over 30 days). Particular attention is paid to the clinical indications for abelacimab, as well as its pharmacokinetic characteristics and administration routes, which are important aspects for its practical application. The second part of the article discusses the potential use of the Boston Scientifi c EKOS ultrasound endovascular thrombectomy system for minimally invasive thrombolysis, which can be combined with the eff ectiveness of abelacimab. A clinical example of the successful use of the EKOS system in a patient with occlusive deep vein thrombosis of the lower extremity is presented. 

антикоагулянтыабелацимабEKOSтромбоз вентромболизисanticoagulantsabelacimabEKOSvenous thrombosisthrombolysisReferencesЗолкин В.Н., Тищенко И.С. Антикоагулянтная терапия в лечении острых тромбозов глубоких и поверхностных вен нижних конечностей. Трудный пациент. 2007;5(15–16):11–15.Zolkin V.N., Tishchenko I.S. Anticoagulant therapy in the treatment of acute thrombosis of deep and superfi cial veins of the lower extremities. Diffi cult patient. 2007;5(15–16):11 –15. (In Russ.)].Raff o C., Capodanno D. Factor XI inhibition in patients with acute coronary syndrome. European Heart Journal Supplements. 2024;26(1):i29-i34. DOI: 10.1093/eurheartjsupp/suae013Raffo C., Capodanno D. Factor XI inhibition in patients with acute coronary syndrome. European Heart Journal Supplements. 2024;26(1):i29-i34. DOI: 10.1093/eurheartjsupp/suae013Ortel T.L., Neumann I., Ageno W., Beyth R., Clark N.P., Cuker A. et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood advances. 2020;4(19):4693–4738. DOI:10.1182/bloodadvances.2020001830Ortel T.L., Neumann I., Ageno W., Beyth R., Clark N.P., Cuker A. et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood advances. 2020;4(19):4693–4738. DOI:10.1182/bloodadvances.2020001830Abraham N.S., Noseworthy P.A., YaoX., Sangaralingham L.R., Shah N.D. Gastrointestinal safety of direct oral anticoagulants: a large population-based study. Gastroenterology. 2017;152(5):1014– 1022. e1. DOI: 10.1053/j.gastro.2016.12.018Abraham N.S., Noseworthy P.A., YaoX., Sangaralingham L.R., Shah N.D. Gastrointestinal safety of direct oral anticoagulants: a large population-based study. Gastroenterology. 2017;152(5):1014– 1022. e1. DOI: 10.1053/j.gastro.2016.12.018Мороз Е.В., Каратеев А.Е., Крюков Е.В., Чернецов В.А. Желудочно-кишечные кровотечения при использовании новых пероральных антикоагулянтов: эпидемиология, факторы риска, лечение и профилактика. Научно-практическая ревматология. 2017;55(6):675–684. DOI: 10.14412/1995-4484-2017-675-684Moroz E.V., Karateev A.E., Kryukov E.V., Chernetsov V.A. Gastrointestinal bleeding with the use of new oral anticoagulants: epidemiology, risk factors, treatment and prevention. Scientifi c and practical rheumatology. 2017;55(6):675–684. (In Russ.)]. DOI: 10.14412/1995-4484-2017-675-684Воробьева Н.М., Малая И.П., Лелькова А.М., Ткачева О.Н. Возможности защиты желудочно-кишечного тракта при применении пероральных антикоагулянтов прямого действия у пациентов с фибрилляцией предсердий. Клинический разбор в общей медицине. 2022(3):43–49.DOI: 10.47407/kr2022.3.3.00133Vorobyova N.M., Malaya I.P., Lelkova A.M., Tkacheva O.N. Possibilities of gastrointestinal tract protection when using direct-acting oral anticoagulants in patients with atrial fi brillation. Clinical analysis in general medicine. 2022(3):43–49. (In Russ.)]. DOI: 10.47407/kr2022.3.3.00133Barnes G.D. New targets for antithrombotic medications: Seeking to decouple thrombosis from hemostasis. Journal of Thrombosis and Haemostasis. 2024. DOI: 10.1016/j.jtha.2024.12.003Barnes G.D. New targets for antithrombotic medications: Seeking to decouple thrombosis from hemostasis. Journal of Thrombosis and Haemostasis. 2024. DOI: 10.1016/j.jtha.2024.12.003Carlin S. Jakovac M., Budaj A., Eikelboom J. Factor XI inhibition in cardiovascular disease. Polish Archives of Internal Medicine. 2024;134(7–8):16799–16799. DOI: 10.20452/pamw.16799Carlin S. Jakovac M., Budaj A., Eikelboom J. Factor XI inhibition in cardiovascular disease. Polish Archives of Internal Medicine. 2024;134(7–8):16799–16799. DOI: 10.20452/pamw.16799Nolte C.H. Factor XI inhibitors–Rising stars in anti-thrombotic therapy?. Journal of the Neurological Sciences. 2024;464:123157. DOI: 10.1016/j.jns.2024.123157Nolte C.H. Factor XI inhibitors–Rising stars in anti-thrombotic therapy?. Journal of the Neurological Sciences. 2024;464:123157. DOI: 10.1016/j.jns.2024.123157Gailani D. Making anticoagulation safer. The Lancet. 2022; 399(10333):1360–1361. DOI: 10.1016/S0140-6736(22)00563-3Gailani D. Making anticoagulation safer. The Lancet. 2022; 399(10333):1360–1361. DOI: 10.1016/S0140-6736(22)00563-3Меркулова И.П. Патофизиология системы крови : учеб.-метод. Пособие. И.П. Меркулова. 2-е изд. Минск: МГЭУ им. А.Д. Сахарова, 2012:120.Merkulova, I. P. Pathophysiology of the blood system: a teaching aid. I.P. Merkulova. 2nd ed. Minsk: Moscow State University of Economics and Finance, 2012:120. (In Russ.)].Аналеев А.И., Семитко С.П., Чернышева И.Е., Беликов Н.В., Хайдукова И.В., Борде А.С. и др. Ультразвук-ассистированная внутрисосудистая терапия: история вопроса и перспективы развития. Consilium Medicum. 2024;26(1):12–19. DOI: 10.26442/20751753.2024.1.202586Analeev A.I., Semitko S.P., Chernysheva I.E., Belikov N.V., Khaidukova I.V., Borde A.S. et al. Ultrasound-assisted intravascular therapy: history of the issue and development prospects. Consilium Medicum. 2024;26(1):12–19. (In Russ.)]. DOI: 10.26442/20751753.2024.1.202586Ferri N., Colombo E., Corsini A. Drug–drug interactions of FXI inhibitors: clinical relevance. Hematology reports. 2024;16(1):151–163. DOI: 10.3390/hematolrep16010016Ferri N., Colombo E., Corsini A. Drug–drug interactions of FXI inhibitors: clinical relevance. Hematology reports. 2024;16(1):151–163. DOI: 10.3390/hematolrep16010016Fioretti A.M., Leopizzi T., La Forgia D., De Luca R., Oreste D., Inchingolo R. et al. Abelacimab in cancer-associated thrombosis: the right drug at the right time for the right purpose. A comprehensive review. Reviews in Cardiovascular Medicine. 2023;24(10):295. DOI: 10.31083/j.rcm2410295Fioretti A.M., Leopizzi T., La Forgia D., De Luca R., Oreste D., Inchingolo R. et al. Abelacimab in cancer-associated thrombosis: the right drug at the right time for the right purpose. A comprehensive review. Reviews in Cardiovascular Medicine. 2023;24(10):295. DOI: 10.31083/j.rcm2410295Yi B.A., Freedholm D., Widener N., Wang X., Simard E., Cullen C. et al. Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa. Journal of Thrombosis and Haemostasis. 2022;20(2):307–315. DOI:10.1111/jth.15577Yi B.A., Freedholm D., Widener N., Wang X., Simard E., Cullen C. et al. Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa. Journal of Thrombosis and Haemostasis. 2022;20(2):307–315. DOI:10.1111/jth.15577Бицадзе В.О., Слуханчук Е.В., Хизроева Д.Х., Третьякова М.В., Цибизова В.И., Гашимова Н.Р. и др. Антикоагулянты: методы контроля дозы и ингибиторы. Акушерство, гинекология и репродукция. 2022;16(2):158–175.Bitsadze V.O., Slukhanchuk E.V., Khizroeva D.Kh., Tretyakova M.V., Tsibizova V.I., Gashimova N.R. et al. Anticoagulants: dose control methods and inhibitors. Obstetrics, Gynecology and Reproduction. 2022;16(2):158–175. (In Russ.)]. DOI: 10.17749/2313-7347/ob.gyn.rep.2022.293Яковлева Д.Р., Степченко М.А., Мещерина Н.С. Генно-инженерные биологические препараты: окно возможности в кардиологической практике. Кардиология: Новости. Мнения. Обучение. 2024;12(4 (39)):66–74.Yakovleva D.R., Stepchenko M.A., Meshcherina N.S. Genetically engineered biological drugs: a window of opportunity in cardiology practice. Cardiology: News. Opinions. Training. 2024;12(4 (39)):66–74. (In Russ.)]. DOI: 10.33029/2309-1908-2024-12-4-66-74Keizer R.J., Huitema A.D., Schellens J.H., Beijnen J.H. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clinical pharmacokinetics. 2010;49(8):493–507. DOI: 10.2165/11531280-000000000-00000Keizer R.J., Huitema A.D., Schellens J.H., Beijnen J.H. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clinical pharmacokinetics. 2010;49(8):493–507. DOI: 10.2165/11531280-000000000-00000Campello E., Simioni P., Prandoni P., Ferri N. Clinical pharmacology of factor XI inhibitors: new therapeutic approaches for prevention of venous and arterial thrombotic disorders. Journal of clinical medicine. 2022;11(21):6314. DOI:10.3390/jcm11216314Campello E., Simioni P., Prandoni P., Ferri N. Clinical pharmacology of factor XI inhibitors: new therapeutic approaches for prevention of venous and arterial thrombotic disorders. Journal of clinical medicine. 2022;11(21):6314. DOI:10.3390/jcm11216314Occhipinti G., Laudani C., Spagnolo M., Finocchiaro S., Mazzone P.M., Faro D.C. et al. Pharmacological and clinical appraisal of factor XI inhibitor drugs. European Heart Journal-Cardiovascular Pharmacotherapy. 2024;10(3):245–258. DOI: 10.1093/ehjcvp/pvae002Occhipinti G., Laudani C., Spagnolo M., Finocchiaro S., Mazzone P.M., Faro D.C. et al. Pharmacological and clinical appraisal of factor XI inhibitor drugs. European Heart Journal-Cardiovascular Pharmacotherapy. 2024;10(3):245–258. DOI: 10.1093/ehjcvp/pvae002Verhamme P., Yi B.A., Segers A., Salter J., Bloomfi eld D., Büller H.R. et al. Abelacimab for prevention of venous thromboembolism. New England Journal of Medicine. 2021;385(7):609–617. DOI:10.1056/NEJMoa2105872Verhamme P., Yi B.A., Segers A., Salter J., Bloomfi eld D., Büller H.R. et al. Abelacimab for prevention of venous thromboembolism. New England Journal of Medicine. 2021;385(7):609–617. DOI:10.1056/NEJMoa2105872Żuk-Łapan A., Jakubik O., Pałuchowski M., Gajewska M., Rogula S., Łomiak M., Gąsecka A. Targeting factor XI as a compromise between thrombosis and bleeding. Cardiology Journal. 2025. DOI: 10.5603/cj.102145Żuk-Łapan A., Jakubik O., Pałuchowski M., Gajewska M., Rogula S., Łomiak M., Gąsecka A. Targeting factor XI as a compromise between thrombosis and bleeding. Cardiology Journal. 2025. DOI: 10.5603/cj.102145Raff o C., Di Leo G., Capodanno D. Factor XI inhibitors and atrial fi brillation: imminent breakthrough or false start? European Heart Journal Supplements. 2025;27(3):iii46–iii53. DOI: 10.1093/eurheartjsupp/suaf015Raff o C., Di Leo G., Capodanno D. Factor XI inhibitors and atrial fi brillation: imminent breakthrough or false start? European Heart Journal Supplements. 2025;27(3):iii46–iii53. DOI: 10.1093/eurheartjsupp/suaf015Ruff C.T., Patel S.M., Giugliano R.P., Morrow D.A., Hug B., Kuder J.F. et al. Abelacimab versus rivaroxaban in patients with atrial fi brillation. New England Journal of Medicine. 2025;392(4):361–371. DOI: 10.1056/NEJMoa2406674Ruff C.T., Patel S.M., Giugliano R.P., Morrow D.A., Hug B., Kuder J.F. et al. Abelacimab versus rivaroxaban in patients with atrial fi brillation. New England Journal of Medicine. 2025;392(4):361–371. DOI: 10.1056/NEJMoa2406674Grafeneder J., Langer G., Schoergenhofer C., Eskandary F., Jilma B., Khder Y., Kovacevic Miljevic K.D. The factor XI/XIa anti body abelacimab combined with enoxaparin inhibits fi lter clotting in hemodialysis circuits ex vivo. Journal of Thrombosis and Thrombolysis. 2024;57(8):1339–1348. DOI: 10.1007/s11239-024-03059-xGrafeneder J., Langer G., Schoergenhofer C., Eskandary F., Jilma B., Khder Y., Kovacevic Miljevic K.D. The factor XI/XIa anti body abelacimab combined with enoxaparin inhibits fi lter clotting in hemodialysis circuits ex vivo. Journal of Thrombosis and Thrombolysis. 2024;57(8):1339–1348. DOI: 10.1007/s11239-024-03059-xSiegel R.J., Luo H. Ultrasound thrombolysis. Ultrasonics. 2008;48(4):312–320. DOI: 10.1016/j.ultras.2008.03.010Siegel R.J., Luo H. Ultrasound thrombolysis. Ultrasonics. 2008;48(4):312–320. DOI: 10.1016/j.ultras.2008.03.010Rosenschein U., Roth A., Rassin T., Basan S., Laniado S., Miller H. I. Analysis of coronary ultrasound thrombolysis endpoints in acute myocardial infarction (ACUTE trial) Results of the feasibility phase. Circulation. 1997;95(6):1411–1416. DOI: 10.1161/01.cir.95.6.1411Rosenschein U., Roth A., Rassin T., Basan S., Laniado S., Miller H. I. Analysis of coronary ultrasound thrombolysis endpoints in acute myocardial infarction (ACUTE trial) Results of the feasibility phase. Circulation. 1997;95(6):1411–1416. DOI: 10.1161/01.cir.95.6.1411Piazza G., Hohlfelder B., Jaff M.R., Ouriel K., Engelhardt T.C., Sterling K.M. et al. A prospective, single-arm, multicenter trial of ultrasound-facilitated, catheter-directed, low-dose fi brinolysis for acute massive and submassive pulmonary embolism: the SEATTLE II study. Cardiovascular Interventions. 2015;8(10):1382–1392 DOI: 10.1016/j.jcin.2015.04.020Piazza G., Hohlfelder B., Jaff M.R., Ouriel K., Engelhardt T.C., Sterling K.M. et al. A prospective, single-arm, multicenter trial of ultrasound-facilitated, catheter-directed, low-dose fi brinolysis for acute massive and submassive pulmonary embolism: the SEATTLE II study. Cardiovascular Interventions. 2015;8(10):1382–1392 DOI: 10.1016/j.jcin.2015.04.020Ouriel K., Veith F.J., Sasahara A.A. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. New England Journal of Medicine. 1998;338(16):1105–1111. DOI: 10.1056/NEJM199804163381603Ouriel K., Veith F.J., Sasahara A.A. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. New England Journal of Medicine. 1998;338(16):1105–1111. DOI: 10.1056/NEJM199804163381603Wissgott C., Richter A., Kamusella P., Steinkamp H. J. Treatment of critical limb ischemia using ultrasound-enhanced thrombolysis (PARES Trial): fi nal results. Journal of Endovascular Therapy. 2007;14(4):438–443. DOI: 10.1177/152660280701400402Wissgott C., Richter A., Kamusella P., Steinkamp H. J. Treatment of critical limb ischemia using ultrasound-enhanced thrombolysis (PARES Trial): fi nal results. Journal of Endovascular Therapy. 2007;14(4):438–443. DOI: 10.1177/152660280701400402Kucher N., Boekstegers P., Müller O.J., Kupatt C., Beyer-Westendorf J., Heitzer T. et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation. 2014;129(4):479–486. DOI: 10.1161/CIRCULATIONAHA.113.005544Kucher N., Boekstegers P., Müller O.J., Kupatt C., Beyer-Westendorf J., Heitzer T. et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation. 2014;129(4):479–486. DOI: 10.1161/CIRCULATIONAHA.113.005544Tapson V.F., Sterling K., Jones N., Elder M., Tripathy U., Brower J. et al. A randomized trial of the optimum duration of acoustic pulse thrombolysis procedure in acute intermediate-risk pulmonary embolism: the OPTALYSE PE trial. JACC: Cardiovascular Interventions. 2018;11(14):1401–1410. DOI: 10.1016/j.jcin.2018.04.008Tapson V.F., Sterling K., Jones N., Elder M., Tripathy U., Brower J. et al. A randomized trial of the optimum duration of acoustic pulse thrombolysis procedure in acute intermediate-risk pulmonary embolism: the OPTALYSE PE trial. JACC: Cardiovascular Interventions. 2018;11(14):1401–1410. DOI: 10.1016/j.jcin.2018.04.008Sterling K.M., Goldhaber S.Z., Sharp A.S.P., Kucher N., Jones N., Maholic R. et al. Prospective multicenter international registry of ultrasound-facilitated catheter-directed thrombolysis in intermediate- high and high-risk pulmonary embolism (KNOCOUT PE). Circulation: Cardiovascular Interventions. 2024;17(3):e013448. DOI: 10.1161/CIRCINTERVENTIONS.123.013448Sterling K.M., Goldhaber S.Z., Sharp A.S.P., Kucher N., Jones N., Maholic R. et al. Prospective multicenter international registry of ultrasound-facilitated catheter-directed thrombolysis in intermediate- high and high-risk pulmonary embolism (KNOCOUT PE). Circulation: Cardiovascular Interventions. 2024;17(3):e013448. DOI: 10.1161/CIRCINTERVENTIONS.123.013448Klok F.A., Piazza G., Sharp A.S., Ainle F.N., Jaff M.R., Chauhan N. et al. Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO study. American heart journal. 2022;(251):43–53. DOI: 10.1016/j.ahj.2022.05.011Klok F.A., Piazza G., Sharp A.S., Ainle F.N., Jaff M.R., Chauhan N. et al. Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO study. American heart journal. 2022;(251):43–53. DOI: 10.1016/j.ahj.2022.05.011Marmagkiolis K., Lendel V., Cilingiroglu M. EKOS™ ultrasound–accelerated catheter–directed thrombolysis for acutely occluded femoro-popliteal graft. Cardiovascular Revascularization Medicine. 2014;15(1):43–45. DOI: 10.1016/j.carrev.2013.12.001Marmagkiolis K., Lendel V., Cilingiroglu M. EKOS™ ultrasound–accelerated catheter–directed thrombolysis for acutely occluded femoro-popliteal graft. Cardiovascular Revascularization Medicine. 2014;15(1):43–45. DOI: 10.1016/j.carrev.2013.12.001Pinsdorf D., Messiha D., Knuschke R., Petrikhovich O., Lortz J., Jánosi R. A., Rassaf T., Rammos C. Comparison of ultrasoundassisted thrombolysis and mechanical thrombectomy in intermediatehigh-risk pulmonary embolism. Vasa. 2025;54(6):406–413. DOI: 10.1024/0301-1526/a001180Pinsdorf D., Messiha D., Knuschke R., Petrikhovich O., Lortz J., Jánosi R. A., Rassaf T., Rammos C. Comparison of ultrasoundassisted thrombolysis and mechanical thrombectomy in intermediatehigh-risk pulmonary embolism. Vasa. 2025;54(6):406–413. DOI: 10.1024/0301-1526/a001180Robles K.E., Armbruster A.L., Austin S.E., Baker J.N. Utilization of EKOS in patients with pulmonary embolism. Innovations. 2022;17(1):30–36. DOI: 10.1177/15569845211057882Robles K.E., Armbruster A.L., Austin S.E., Baker J.N. Utilization of EKOS in patients with pulmonary embolism. Innovations. 2022;17(1):30–36. DOI: 10.1177/15569845211057882

The authors declare that there are no conflicts of interest present.